Benzinga··Vandana SinghAbbVie's Skyrizi Posts Strong Remission Data, Challenges J&J in Crohn's Market
AbbVie's Skyrizi achieved 55% remission rate in Crohn's patients versus 30% placebo, strengthening competitive positioning against Johnson & Johnson's Tremfya.
JNJABBVimmunologyCrohn's disease